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ABSTRACT 
Human Immunodeficiency Virus (HIV) is an enveloped virus, belonging to the viral family Retroviridae. It is a highly evolved virus which has 
grasped the attention of all researchers with its special features like morphology, genetics and also by its emerging nature 3. The special feature 
of all retro viruses is the presence of an enzyme called Reverse transcriptase which plays major role in reverse transcription process4. HIV 
enters the host body, damages immune system and will cause life-threatening opportunistic infections finally leads to AIDS (Acquired 
Immunodeficiency Syndrome).Many advances have been made in the prevention of HIV transmission and management of HIV/AIDS since the 
virus was discovered in the early 1980s7. One of the most important discoveries has been antiretroviral treatment, which can halt the 
replication of HIV and ease symptoms, turning AIDS into a chronic condition instead of a rapidly terminal illness. Despite advances, HIV remains 
a major public health challenge. This article reviews the genus, life cycle, and transmission of HIV, as well as workplace issues surrounding the 
virus and the challenges of developing an HIV vaccine12. 
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INTRODUCTION OF AIDS  
Definition 
AIDS is the last stage in a progression of diseases resulting 
from a viral infection known as the Human 
Immunodeficiency Virus (HIV or AIDS virus). The diseases 
include a number of unusual and severe infections, cancers 
and debilitating illnesses, resulting in severe weight loss or 
wasting away, and diseases affecting the brain and central 
nervous system6. There is no cure for HIV infection or AIDS 
nor is there a vaccine to prevent HIV infection. However, 
new medications not only can slow the progression of the 
infection, but can also markedly suppress the virus, thereby 
restoring the body’s immune function and permitting many 
HIV-infected individuals to lead a normal, disease-free life8. 
Description  
The immune system is a network of cells, organs and 
proteins that work together to defend and protect the body 
from potentially harmful, infectious microorganisms 
(microscopic life-forms), such as bacteria, viruses, parasites 
and fungi14. The immune system also plays a critical role in 
preventing the development and spread of many types of 
cancer. When the immune system is missing one or more of 
its components, the result is an immunodeficiency   disorder. 
AIDS is an immunodeficiency disorder17. 
Lymphocytes (white blood cells) are one of the main types of 
immune cells that make up the immune system20. There are 
two types of lymphocytes: B cells and T cells. (T cells are also 
called CD4 cells, CD4 T cells, or CD4 cell lymphocytes). B 
cells secrete antibodies (proteins) into the body's fluids to 
ambush and attack antigens (foreign proteins such as 
bacteria, viruses or fungi)25. T cells directly attack and 
destroy infected or malignant cells in the body. There are 
two types of T cells: helper T cells and killer T cells. Helper T 
cells recognize the antigen and activate the killer T cells. 
Killer T cells then destroy the antigen4. When HIV is 
introduced into the body, this virus is too strong for the 
helper T cells and killer T cells. The virus then invades these 
cells and starts to reproduce itself, thereby not only killing 
the CD4 T cells, but also spreading to infect otherwise 
healthy cells5. The HIV virus cannot be destroyed and lives in 
the body undetected for months or years before any sign of 
illness appears. Gradually, over many years or even decades, 
as the T cells become progressively destroyed or inactivated, 
other viruses, parasites or cancer cells (called "opportunistic 
diseases") which would not have been able to get past a 
healthy body's defense, can multiply within the body 
without fear of destruction4. Commonly seen opportunistic 
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diseases in persons with HIV infection include: 
pneumocystis carinii pneumonia, tuberculosis, candida 
(yeast) infection of the mouth, throat or vagina, shingles, 
cytomegalovirus retinitis and kaposi's sarcoma9.  
The first cases of acquired immunodeficiency syndrome 
(AIDS) were reported in the United States in the spring of 
198111. By 1983 the human immunodeficiency virus (HIV), 
the virus that causes AIDS, had been isolated. Early in the 
U.S. HIV/AIDS pandemic, the role of substance abuse in the 
spread of AIDS was clearly established. Injection drug use 
(IDU) was identified as a direct route of HIV infection and 
transmission among injection drug users13. The largest 
group of early AIDS cases comprised gay and bisexual men. 
Early cases of HIV infection that were sexually transmitted 
often were related to the use of alcohol and other 
substances, and the majority of these cases occurred in 
urban, educated17. 
Currently, injection drug users represent the largest HIV-
infected substance-abusing population in the United States. 
HIV/AIDS prevalence rates among injection drug users vary 
by geographic region, with the highest rates in surveyed 
substance abuse treatment centers in the Northeast, the 
South, and Puerto Rico22. From July 1998 through June 1999, 
23 percent of all AIDS cases reported were among men and 
women who reported IDU (Centers for Disease Control and 
Prevention [CDC], 1999).IDU practices are quick and 
efficient vehicles for HIV transmission. The virus is 
transmitted primarily through the exchange of blood using 
needles, syringes, or other IDU equipment (e.g. cookers, 
rinse water, cotton) that were previously used by an HIV-
infected person. Lack of knowledge about safer needle use 
techniques and the lack of alternatives to needle sharing 
(e.g., available supplies of clean, new needles) contribute to 
the rise of HIV/AIDS. Another route of HIV transmission 
among injection drug users is through sexual contacts within 
relatively closed sexual networks, which are characterized 
by multiple sex partners, unprotected sexual intercourse, 
and exchange of sex for money21. The inclusion of alcohol 
and other no injection substances to this lethal mixture only 
increases the HIV/AIDS caseload. A major risk factor for 
HIV/AIDS among injection drug users is crack use; one study 
found that crack abusers reported more sexual partners in 
the last 12 months, more sexually transmitted diseases 
(STDs) in their lifetimes, and greater frequency of paying for 
sex, exchanging sex for drugs, and having sex with injection 
drug users. 
HIV TRANSMISSION 
HIV cannot survive outside of a human cell. HIV must be 
transmitted directly from one person to another through 
human body fluids that contain HIV-infected cells, such as 
blood, semen, vaginal secretions, or breast milk. The most 
effective means of transmitting HIV is by direct contact 
between the infected blood of one person and the blood 
supply of another. (See Figure 1-1 for an illustration of the 
structure of the virus.) This can occur in childbirth as well as 
through blood transfusions or organ transplants prior to 
1985. (Testing of the blood supply began in 1985, and the 
chance of this has greatly decreased.) Using injection 
equipment that an infected person used is another direct 
way to transmit HIV11.   
 
Figure 1-1: Parts of HIV. 
Sexual contact is also an effective transmission route for HIV 
because the tissues of the anus, rectum, and vagina are 
mucosal surfaces that can contain infected human body 
fluids and because these surfaces can be easily injured, 
allowing the virus to enter the body. A person is about five 
times more likely to contract HIV through anal intercourse 
than through vaginal intercourse because the tissues of the 
anal region are more prone to breaks and bleeding during 
sexual activity. 
A woman is eight times more likely to contract HIV through 
vaginal intercourse if the man is infected than in the reverse 
situation (Center for AIDS Prevention Studies, 1998)23. HIV 
can be passed from a woman to a man during intercourse, 
but this is less likely because the skin of the penis is not as 
easily damaged. Female-to-female transmission of HIV 
apparently is rare but should be considered a possible 
means of transmission because of the potential exposure of 
mucous membranes to vaginal secretions and menstrual 
blood. Oral intercourse also is a potential risk but is less 
likely to transmit the disease than anal or vaginal 
intercourse. Saliva seems to have some effect in helping 
prevent transmission of HIV, and the oral tissues are less 
likely to be injured in sexual activity than those of the vagina 
or anus. However, if a person has infections or injuries in the 
mouth or gums, then the risk of contracting HIV through oral 
sex increases18. 
Role of circumcision in male infectivity: 
A possible link between male circumcision and HIV 
infectivity was first observed during studies conducted in 
Kenya in the late 1980s. Since then, numerous studies have 
been done on the possible relationship between male 
circumcision and HIV infectivity. Data have not revealed a 
direct causal link between circumcision and HIV 
transmission, and scientific opinion has been divided on this 
topic. While some studies indicate that circumcision can play 
a protective role in preventing HIV infection17. The bulk of 
recent scientific research has concluded that the reverse is 
true and that circumcision can actually increase the rate of 
HIV transmission. Clearly, further research and analysis of 
circumcision as a prophylactic against HIV transmission is 
needed19 
Risks of Transmission: 
Several factors can increase the risk of HIV transmission. 
One factor is the presence of another STD (e.g., genital ulcer 
Pawar et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(3):599-608 
ISSN: 2250-1177                                                                                    [601]                                                                                    CODEN (USA): JDDTAO 
disease) in either partner, which increases the risk of 
becoming infected with HIV through sexual contact. This is 
because the same risk behaviors that resulted in the person 
contracting an STD increase that person's chance of 
contracting HIV15. STDs also can cause genital lesions that 
serve as ports of entry for HIV, they can increase the number 
of HIV target cells (CD4+ T cells), and they can cause the 
person to shed greater concentrations of HIV (CDC, 1998a). 
For this reason, all sexually active clients, especially women, 
should be checked regularly for STDs such as gonorrhea and 
chlamydia. Many STDs that cause symptoms in men are 
asymptomatic in women. When genital ulcers are treated 
and heal, the risk of HIV transmission is reduced. 
Another factor that increases risk is a high level of HIV 
circulating in the bloodstream. This occurs soon after the 
initial infection and returns late in the disease16. New drug 
therapy can keep this level (called viral load) low or 
undetectable, but this does not mean that other individuals 
cannot be infected. The virus still exists--it is simply not 
detectable by the currently available tests. Because the 
correlation between plasma and genital fluid viral load 
varies, transmission may still occur despite an undetectable 
serum viral load12. Once HIV passes to an uninfected person 
who is not taking anti-HIV drugs, the virus reproduces very 
rapidly. It is known that drug-resistant viruses can be 
transmitted from one person to another. The treatment 
implications for a person infected with a drug-resistant virus 
are not yet known, but treatment will likely be difficult.20 
There are many misconceptions regarding HIV transmission. 
For example, HIV is not passed from one person to another 
in normal daily contact that does not involve either exposure 
to blood or sexual contact. It is not carried by mosquitoes 
and cannot be caught from toilet seats or from eating food 
prepared by someone with AIDS. No one has ever contracted 
AIDS by kissing someone with AIDS, or even by sharing a 
toothbrush (although sharing a toothbrush still is not 
advised)10. Other misconceptions people may have included 
the following: "It can't happen to me."--HIV can infect 
anyone who has sex with or shares injection equipment 
with, someone who is infected. "I would know if my sex 
partner (injection partner) were infected."--Most people 
infected with HIV do not look or feel sick and do not even 
know they are infected. 
"As long as I get treated for any sexual infections I pick up, 
I'll be safe."--No current form of treatment can cure or 
prevent HIV, and although treating other infections reduces 
risk, there is still a high chance of getting HIV through 
unprotected sex or sharing injection equipment9. "If I'm only 
with one sexual partner, and don't share injection 
equipment, I don't need to worry about HIV."--This is true 
only if the partner is uninfected and has no ongoing risk of 
infection. If the partner is or becomes infected, then anyone 
who has sex with him or shares his injection equipment is at 
high risk for HIV, and the only way to detect infection is to be 
tested. "If I douche or wash after sex, I won't get HIV."--
Douching and washing will not prevent HIV. "If I don't share 
my own syringe, I won't get HIV."--HIV can also be spread 
through shared cookers, filters, and the prepared drug5. 
Life Cycle of HIV: 
It is possible to prevent transmission even after exposure to 
HIV. In San Francisco, postexposure prophylaxis is being 
offered to people who believe they have high risk for HIV 
transmission because of exposure with a known or 
suspected HIV-infected individual. Treatment is started 
within 72 hours of exposure and includes combination 
therapy, which may include a protease inhibitor, for a period 
of 1 month and follow up for 12 months2. 
Once an HIV particle enters a person's body, it binds to the 
surface of a target cell (CD4+ T cell). The virus enters 
through the cell's outer envelope by shedding its own viral 
envelope, allowing the HIV particle to release an HIV 
ribonucleic acid (RNA) chain into the cell, which is then 
converted into deoxyribonucleic acid (DNA)14. The HIV DNA 
enters the cell's nucleus and is copied onto the cell's 
chromosomes. This causes the cell to begin reproducing 
more HIV, and eventually the cell releases more HIV 
particles. These new particles then attach to other target 
cells, which become infected. Figure 1-2 illustrates how HIV 
enters a CD4+ T cell and reproduces.   
 
Figure 1-2: Diagram of HIV Entering Cell and Reproducing. 
Measuring HIV in the Blood: 
Physicians can measure the presence of HIV in a person by 
means of (1) the CD4+ T cell count and (2) the viral load 
count. The CD4+ T cell count measures the number of CD4+ 
T cells (i.e., white blood cells) in a milliliter of blood. These 
are the cells that HIV is most likely to infect, and the number 
of these cells reflects the overall health of a person's immune 
system.CD4+ T cells act as signals to inform the body's 
immune system that an infection exists and needs to be 
fought4. Because HIV hides inside the very cells responsible 
for signaling its presence, it can survive and reproduce 
without the infected person knowing of its existence for 
many years. Even though the body can produce sufficient 
CD4+ T cells to replace the billions that are destroyed by 
untreated HIV each day, eventually HIV kills so many CD4+ T 
cells that the damaged immune system cannot control other 
infections that may make the person sick. This is the late 
stage of HIV, when AIDS is often diagnosed based on the 
presence of specific illnesses (i.e., opportunistic infections)18. 
The viral load represents the level of HIV RNA (genetic 
material) circulating in the bloodstream. This level becomes 
very high soon after a person is initially infected with HIV, 
then it drops. Viral load tests measure the number of copies 
of the virus in a milliliter of plasma; currently available tests 
can measure down to 50 copies per milliliter, and even more 
sensitive tests can measure down to 5 copies per milliliter. 
To explain the relationship between CD4+ T cell count and 
viral load count and how together they are used to gauge a 
person's stage in disease progression, a "moving train" 
analogy can be used. The CD4+ T cell count is used to 
measure the person's distance to the point of high risk of 
contracting opportunistic infections, or death. The viral load 
Pawar et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(3):599-608 
ISSN: 2250-1177                                                                                    [602]                                                                                    CODEN (USA): JDDTAO 
count is used to measure the rate at which CD4+ T cells are 
being destroyed19. Therefore, the CD4+ T cell count is the 
train's position on the track, and the viral load is the train's 
speed toward the outcome (i.e., AIDS and then death). After a 
person is infected with HIV, the body takes about 6 to 12 
weeks and sometimes as long as 6 months to build up 
proteins to fight the virus. These proteins are called HIV 
antibodies (disease-fighting proteins) and are detected by an 
HIV test called the ELISA (enzyme-linked immunosorbent 
assay)5 The ELISA is very sensitive--it almost always detects 
HIV if it is there. Rarely, ELISA tests will give false-positive 
readings (a positive test in someone uninfected). For this 
reason, a positive ELISA test must always be confirmed with 
a second, more specific test called the Western blot. 
According to the CDC, the accuracy of the ELISA and the 
Western blot together is greater than 99 percent. Rapid HIV 
tests and home sample collection tests also are options for 
clients; see Chapter 2 for a more detailed discussion of these 
types of tests.13 The 6 to 12 weeks between the time of 
infection and the time when an ELISA test for HIV becomes 
positive are called the "window period." During this period, 
the individual is extremely infectious to any sexual or 
needle-sharing partner but does not test positive unless a 
more expensive viral load test is performed. The level of 
virus is determined by using a viral load test; three types of 
viral load tests are HIV-RNA polymerase chain reaction 
(PCR), HIV branched DNA (bDNA), and HIV-RNA nucleic acid 
sequence-based amplification (NASBA). Each of these tests 
measures the amount of replicating or reproducing virus in 
the bloodstream; thus a lower value signifies less risk of 
rapid progression17. The best viral load test result is "none 
detected," although this does not mean the virus is gone, 
only that it is not actively reproducing at a measurable 
level12. 
Disease Progression: 
Once a person is infected with HIV, she should understand 
the progression of the disease from initial infection, through 
the latency period, symptomatic infections, and finally AIDS. 
The course of untreated HIV is not known but may go on for 
10 years or longer in many people11. Several years into HIV 
infection, mild symptoms begin to develop, and then later 
severe infections that define AIDS occur. Treatment appears 
to greatly extend the life and improve the quality of life of 
most patients, although estimating survival after an AIDS 
diagnosis is inexact24. 
Initial infection 
 Primary HIV infection can cause an acute retroviral 
syndrome that often is mistaken for influenza (the flu), 
mononucleosis, or a bad cold. This syndrome is reported by 
roughly half of those who contract HIV (Russell and 
Sepkowitz, 1998) and generally occurs between 2 and 6 
weeks after infection. Symptoms may include fever, 
headache, sore throat, fatigue, body aches, weight loss, and 
swollen lymph nodes. Other symptoms are a rash, mouth or 
genital ulcers, diarrhea, nausea and vomiting, and thrush. 
The CD4+ T cell count can drop very low during the early 
weeks, although it usually returns to a normal level after the 
initial illness is over21. The initial illness can last several days 
or even weeks. The greatest spread of HIV occurs 
throughout the body early in the disease. Approximately 6 
months after infection, the level of virions produced every 
day may reach a "set point." A higher set point usually means 
a more rapid progression of HIV disease. Early treatment 
may be recommended to reduce the set point, potentially 
leading to a better chance of controlling the infection. 
Alcohol and drug counselors should discuss symptoms that 
suggest initial HIV infection with their clients and encourage 
clients to be tested for HIV if they experience such 
symptoms. This not only will encourage clients who are 
infected to enter treatment early but also will provide an 
opportunity for the counselor to help uninfected clients 
remain that way13. 
Latency period: 
 After initial infection comes the latency period, or 
incubation period, during which untreated persons with HIV 
have few, if any, symptoms. This period lasts a median of 
about 10 years. The most common symptom during this 
period is lymphadenopathy, or swollen lymph nodes. The 
lymph nodes found around the neck and under the arms 
contain cells that fight infections. Swollen lymph nodes in 
the groin area may be normal and not indicative of HIV. 
When any infection is present, lymph nodes often swell, 
sometimes painfully. With HIV, they swell and tend to stay 
swollen but usually are not painful. 
Early Symptomatic Infection: 
 After the first year of infection, the CD4+ T cell count drops 
at a rate of about 30 to 90 cells per year. When the CD4+ T 
cell count falls below 500, mild HIV symptoms may occur.12 
Many people, however, will have no symptoms at all until 
the CD4+ T cell count has dropped very low (200 or less). 
Bacteria, viruses, and fungi that normally live on and in the 
human body begin to cause diseases that are also known as 
opportunistic infections. Early symptoms of infection may 
include chronic diarrhea, herpes zoster, recurrent vaginal 
candidiasis, thrush, oral hairy leukoplakia (a virus that 
causes white patches in the mouth), abnormal Pap tests, 
thrombocytopenia, or numbness or tingling in the toes or 
fingers. Most of these infections occur with a CD4+ T cell 
count between 200 and 500. Symptoms of these infections 
usually signal a problem with the immune system but are 
not severe enough to be classified as AIDS. Please refer to 
Appendix D for a complete checklist of symptoms17. 
TYPES OF HIV: 
 HIV Types There are two types of HIV that cause AIDS: HIV 
type 1 (HIV-1) and HIV-2. We know little about HIV-2. 
Studies have shown striking similarities but also important 
differences between HIV-1 and HIV-2. They have the same 
modes of transmission and are associated with the same 
opportunistic infections, but HIV-2 appears to progress 
more slowly. Most HIV-2 cases are found in western Africa 
and in countries related to western Africa in some way such 
as Portugal, France, Angola, Mozambique, Brazil, and India. 
Various subtypes of HIV-1 have been found in specific 
geographic areas and in specific high-risk groups1. A person 
can be coinfected with different subtypes. The following are 
HIV-1 subtypes and their geographic distributions: Subtype 
A: Central Africa, sub-Saharan Africa Subtype B: South 
America, Brazil, United States, Thailand, Europe, Caribbean, 
India, Japan Subtype C: Brazil, India, South Africa Subtype D: 
Central Africa, sub-Saharan Africa Subtype E: Thailand, 
Central African Republic, Southeast Asia Subtype F: Brazil, 
Romania, Democratic Republic of Congo (Zaire) Subtype G: 
Democratic Republic of Congo (Zaire), Gabon, Thailand, 
Russia, Central Africa Subtype H: Democratic Republic of 
Congo (Zaire), Gabon, Russia, Central Africa Subtype I: 
Cyprus Subtype O: Cameroon, Gabon. 
TEST of HIV 
Various blood tests now are used to detect HIV. The most 
frequently used test for detecting antibodies to HIV-1 is 
enzyme immunoassay. If it indicates the presence of 
antibodies, the blood is more definitively tested with the 
Western blot method1. A test that measures directly the viral 
Pawar et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(3):599-608 
ISSN: 2250-1177                                                                                    [603]                                                                                    CODEN (USA): JDDTAO 
genes in the blood is helpful in assessing the efficacy of 
treatments. There is no cure for AIDS, but it may be treated 
with a number of different antiretroviral drugs, often in 
combination. Early treatment with retrovirals, as soon as a 
person tests positive for infection with HIV, has been shown 
in studies to reduce to the transmission of HIV. Drugs such 
as AZT, ddI, and 3TC, which are reverse transcriptase 
inhibitors, have proved effective in delaying the onset of 
symptoms in certain subsets of infected individuals. The 
addition of a protease inhibitor, such as saquinovir, 
amprenavir, or atazanavir, to AZT and 3TC has proved very 
effective, but the drug combination does not eliminate the 
virus from the body. Efavirenz (Sustiva), another type of 
reverse transcriptase inhibitor, must be taken with protease 
inhibitors or older AIDS medicines. Highly active 
antiretroviral therapy (HAART), a combination typically of 
three or more anti-AIDS drugs, is now the preferred 
treatment. Opportunistic infections are treated with various 
antibiotics and antivirals, and patients with malignancies 
may undergo chemotherapy3. These measures may prolong 
life or improve the quality of life, but drugs for AIDS 
treatment may also produce painful or debilitating side 
effects. Many experimental AIDS vaccines have been 
developed and tested, but none has yet proved more than 
modestly effective, including some that underwent full-scale 
testing. The development of a successful vaccine against 
AIDS has been slowed because HIV mutates rapidly, causing 
it to become unrecognizable to the immune system, and 
because, unlike most viruses, HIV attacks and destroys 
essential components of the very immune system a vaccine 
is designed to stimulate8 
HIV TREATMENT 
 FDA-Approved HIV Medicines  
Treatment with HIV medicines is called antiretroviral 
therapy (ART). ART is recommended for everyone with HIV. 
People on ART take a combination of HIV medicines (called 
an HIV regimen) every day. A person's initial HIV regimen 
generally includes three HIV medicines from at least two 
different drug classes. ART can’t cure HIV, but HIV medicines 
help people with HIV live longer, healthier lives2. HIV 
medicines also reduce the risk of HIV transmission. The 
following table lists HIV medicines approved by the U.S. 
Food and Drug Administration (FDA) for the treatment of 
HIV infection in the United States. The HIV medicines are 
listed according to drug class and identified by generic and 
brand names. Click on a drug name to view information on 
the drug from the AID Sinfo Drug Database. Or download the 
AID Sinfo Drug Database app to view the information on 
your Apple or Android devices5. 
 
 
 
A) Nucleoside Reverse Transcriptase Inhibitors (NRTIs): 
Abacavir 
 
 
  
Emitricitabin 
 
Lumivudine 
 
Stavudine 
 
Zidovudine 
N
N
O
H
O
O
H
H
O
N
N
N
 
Pawar et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(3):599-608 
ISSN: 2250-1177                                                                                    [604]                                                                                    CODEN (USA): JDDTAO 
B) Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): 
Enfuviretide 
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D) Fusion Inhibitors: 
Enfuvirtide H
N
O
CL
O
C
F
F
F
C
 
E) Integrase Inhibitors: 
Dolutegravir 
 
Elvitegravir 
 
Raltegravir 
 
 
F) Pharmacokinetic Enhancers: 
Cobiciatat 
 
 
MECHANISM OF ACTION OF HIV DRUG: 
When HIV infects a cell, reverse transcriptase copies the viral 
single stranded RNA genome into a double-stranded viral 
DNA. The viral DNA is then integrated into the host 
chromosomal DNA, which then allows host cellular 
processes, such as transcription and translation, to 
reproduce the virus9. RTIs block reverse transcriptase's 
enzymatic function and prevent completion of synthesis of 
the double-stranded viral DNA, thus preventing HIV from 
multiplying. A similar process occurs with other types of 
viruses. The hepatitis B virus, for example, carries its genetic 
material in the form of DNA, and employs a RNA-dependent 
DNA polymerase to replicate. Some of the same compounds 
used as RTIs can also block HBV replication; when used in 
this way they are referred to as polymerase inhibitors10. 
RTIs come in three forms: 
 Nucleoside analog reverse-transcriptase inhibitors 
(NARTIs or NRTIs) 
 Nucleotide analog reverse-transcriptase inhibitors 
(NtARTIs or NtRTIs) 
 Non-nucleoside reverse-transcriptase inhibitors 
(NNRTIs) 
The antiviral effect of NRTIs and NtRTIs is essentially the 
same; they are analogues of the naturally occurring 
deoxynucleotides needed to synthesize the viral DNA and 
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they compete with the natural deoxynucleotides for 
incorporation into the growing viral DNA chain. However, 
unlike the natural deoxynucleotides substrates, NRTIs and 
NtRTIs lack a 3′-hydroxyl group on the deoxyribose moiety. 
As a result, following incorporation of an NRTI or an NtRTI, 
the next incoming deoxynucleotide cannot form the next 5′–
3′phosphodiester bond needed to extend the DNA chain7. 
Thus, when an NRTI or NtRTI is incorporated, viral DNA 
synthesis is halted, a process known as chain termination. All 
NRTIs and NtRTIs are classified as competitive substrate 
inhibitors8. 
Unfortunately, NRTIs/NtRTIs compete as substrates for not 
only viral but also host DNA synthesis, acting as chain 
terminators for both. The former explains 
NRTIs'/NtRTIs'antiviral effect, while the latter explains their 
drug toxicity/side effects. 
In contrast, NNRTIs have a completely different mode of 
action. NNRTIs block reverse transcriptase by binding 
directly to the enzyme. NNRTIs are not incorporated into the 
viral DNA like NRTIs, but instead inhibit the movement of 
protein domains of reverse transcriptase that are needed to 
carry out the process of DNA synthesis. NNRTIs are therefore 
classified as non-competitive inhibitors of reverse 
transcriptase12. 
Nucleoside analog reverse-transcriptase inhibitors 
(NARTIs or NRTIs): 
Nucleoside analog reverse-transcriptase inhibitors (NARTIs 
or NRTIs) compose the first class of antiretroviral drugs 
developed. In order to be incorporated into the viral DNA, 
NRTIs must be activated in the cell by the addition of three 
phosphate groups to their deoxyribose moiety, to form NRTI 
triphosphates. This phosphorylation step is carried out by 
cellular kinase enzymes14. Zidovudine, also called AZT, ZDV, 
and azidothymidine, has the trade name Retrovir. 
Zidovudine was the first antiretroviral drug approved by the 
FDA for the treatment of HIV. Didanosine, also called ddI, 
with the trade names Videx and Videx EC, was the second 
FDA-approved antiretroviral drug. It is an analog of 
adenosine. Zalcitabine, also called ddC and dideoxycytidine, 
has the trade name Hivid. This drug has been discontinued 
by the manufacturer.Stavudine, also called d4T, has trade 
names Zerit and Zerit XR. Lamivudine, also called 3TC, has 
the trade name Zeffix and Epivir. It is approved for the 
treatment of both HIV and hepatitis B. Abacavir, also called 
ABC, has the trade name Ziagen, is an analog of guanosine. 
Emtricitabine, also called FTC, has the trade name Emtriva 
(formerly Coviracil). Structurally similar to lamivudine, it is 
approved for the treatment of HIV and undergoing clinical 
trials for hepatitis B. Entecavir, also called ETV, is a 
guanosine analog used for hepatitis B under the trade name 
Baraclude. It is not approved for HIV treatment17. 
Nucleotide analog reverse-transcriptase inhibitors 
(NtARTIs or NtRTIs): 
As described above, host cells phosphorylate nucleoside 
analogs to nucleotide analogs. The latter serve as poison 
building blocks (chain terminators) for both viral and host 
DNA, causing respectively the desired antiviral effect and 
drug toxicity/side effects20. Taking nucleotide analog 
reverse-transcriptase inhibitors (NtARTIs or NtRTIs) directly 
obviates the initial phosphorylation step. Tenofovir, also 
known as TDF is a so-called 'prodrug' with the active 
compound deactivated by a molecular side chain that 
dissolves in the human body allowing a low dose of tenofovir 
to reach the site of desired activity. One example of the 
prodrug form is tenofovir disoproxil fumarate with the trade 
name Viread (Gilead Sciences Inc USA)25. It is approved in 
the USA for the treatment of both HIV and hepatitis B. 
Adefovir, also known as ADV or bis-POM PMPA, has trade 
names Preveon and Hepsera. It not approved by the FDA for 
treatment of HIV due to toxicity issues, but a lower dose is 
approved for the treatment of hepatitis B.While often listed 
in chronological order, NRTIs/NtRTIs are 
nucleoside/nucleotide analogues of cytidine, guanosine, 
thymidine and adenosine: 
 Thymidine analogues: zidovudine (AZT) and stavudine 
(d4T) 
 Cytidine analogues: zalcitabine (ddC), lamivudine 
(3TC), and emtricitabine (FTC) 
 Guanosine analogues: abacavir (ABC) and entecavir 
(ETV) 
 Adenosine analogues: didanosine (ddI), tenofovir 
(TDF), and adefovir (ADV) 
Non-nucleoside reverse-transcriptase inhibitors 
(NNRTIs): 
Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) 
are the third class of antiretroviral drugs that were 
developed. In all cases, patents remain in force until beyond 
2007.6 This class of drugs was first described at the Rega 
Institute for Medical Research (Belgium)23 
1. Efavirenz (Efavirenz has the trade names Sustiva and 
Stocrin) 
2. Nevirapine  
3. Delavirdine (Delavirdine, currently rarely used, has the 
trade name Rescriptor) 
4. Etravirine  
5. Rilpivirine  
Portmanteau inhibitors: 
Researchers have designed molecules which dually inhibit 
both reverse transcriptase (RT) and integrase (IN). These 
drugs are a type of "portmanteau inhibitors"18. 
Mechanisms of resistance to reverse transcriptase 
inhibitors: 
While NRTIs and NNRTIs alike are effective at terminating 
DNA synthesis and HIV replication, HIV can and eventually 
does develop mechanisms that confer the virus resistance to 
the drugs. HIV-1 RT does not have proof-reading activity17. 
This, combined with selective pressure from the drug, leads 
to mutations in reverse transcriptase that make the virus less 
susceptible to NRTIs and NNRTIs. Aspartate residues 110, 
185, and 186 in the reverse transcriptase polymerase 
domain are important in the binding and incorporation of 
nucleotides14. The side chains of residues K65, R72, and 
Q151 interact with the next incoming nucleotide. Also 
important is L74, which interacts with the template strand to 
position it for base pairing with the nucleotide. Mutation of 
these key amino acids results in reduced incorporation of the 
analogs.13 
NRTI resistance: 
There are two major mechanisms of NRTI resistance. The 
first being reduced incorporation of the nucleotide analog 
into DNA over the normal nucleotide. This results from 
mutations in the N-terminal polymerase domain of the 
reverse transcriptase that reduce the enzyme’s affinity or 
ability to bind to the drug12. A prime example for this 
mechanism is the M184V mutation that confers resistance to 
lamivudine (3TC) and emtricitabine (FTC). Another well 
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characterized set of mutations is the Q151M complex found 
in multi-drug resistant HIV which decreases reverse 
transcriptase’s efficiency at incorporating NRTIs, but does 
not affect natural nucleotide incorporation. The complex 
includes Q151M mutation along with A62V, V75I, F77L, and 
F116Y. A virus with Q151M alone is intermediately resistant 
to zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), 
stavudine (d4T), and slightly resistant to abacavir (ABC). A 
virus with Q151M complexed with the other four mutations 
becomes highly resistant to the above drugs, and is 
additionally resistant to lamivudine (3TC) and emtricitabine 
(FTC).8 
 The second mechanism is the excision or the hydrolytic 
removal of the incorporated drug or pyrophosphorlysis. This 
is a reverse of the polymerase reaction in which the 
pyrophosphate/PPI released during nucleotide 
incorporation reacts with the incorporated drug 
(monophosphate) resulting in the release of the triphosphate 
drug.5 This ‘unblocks’ the DNA chain, allowing it to be 
extended, and replication to continue. Excision enhancement 
mutations, typically M41L, D67N, K70R, L210W, T215Y/F, 
and K219E/Q, are selected for by thymidine analogs AZT and 
D4T; and are therefore called thymidine analog mutations 
(TAMs).Other mutations including insertions and deletions 
in the background of the above mutations also confer 
resistance via enhanced excision4. 
NNRTI resistance: 
NNRTIs do not bind to the active site of the polymerase but 
in a less conserved pocket near the active site in the p66 
subdomain. Their binding results in a conformational change 
in the reverse transcriptase that distorts the positioning of 
the residues that bind DNA, inhibiting polymerization.11  
Mutations in response to NNRTIs decrease the binding of the 
drug to this pocket. Treatment with a regimen including 
efavirenz (EFV) and nevirapine (NVP) typically results in 
mutations L100I, Y181C/I, K103N, V106A/M, V108I, 
Y188C/H/L and G190A/S17. There are three main 
mechanisms of NNRTI resistance. In the first NRTI mutations 
disrupt specific contacts between the inhibitor and the 
NNRTI binding pocket. An example of this is K103N and 
K101E which sit at the entrance of the pocket, blocking the 
entrance/binding of the drug. A second mechanism is the 
disruption of important interactions on the inside of the 
pocket. For example Y181C and Y188L result in the loss of 
important aromatic rings involved in NNRTI binding12. The 
third type of mutations result in changes in the overall 
conformation or the size of the NNRTI binding pocket. An 
example is G190E, which creates a steric bulk in the pocket, 
leaving little or no room for an NNRTI to tightly bind13. 
SYMPTOMS OF HIV 
The initial stage of HIV is known as primary HIV infection or 
seroconversion. Many people develop symptoms, although 
they might not recognise them at the time. Their symptoms 
usually occur two to six weeks after they are infected with 
HIV18. 
Symptoms of primary HIV infection include: 
 Fever 
 Sore throat 
 Tiredness 
 Joint pain 
 Muscle pain 
 Swollen glands (nodes) 
 A blotchy rash 
These early symptoms are often very mild, so it is easy to 
mistake them for another condition, such as a cold or 
glandular fever. However, it is unusual to get these 
symptoms in association with a rash, so anyone concerned 
about the risk of HIV infection should request a test2,5. After 
the initial symptoms have gone, HIV will often not cause any 
further symptoms for many years. This is known as 
asymptomatic HIV infection. During this time, the virus is 
still reproducing and damaging your immune system. 
 Possible symptoms of a serious infection caused by a 
damaged immune system include: 
 Persistent tiredness 
 Night sweats 
 Unexplained weight loss 
 Persistent diarrhoea 
 Blurred vision 
 White spots on your tongue or mouth 
 Dry cough 
 Shortness of breath 
 A fever of above 37C (100F) that lasts a number of 
weeks 
 Swollen glands that last for more than three months 
AIDS-related illnesses, such as TB, pneumonia and some 
cancers, may appear. Many of these, though serious, can be 
treated to some extent and some are likely to improve if you 
start treatment and your CD4 count increases1,5.7. 
CAUSES OF HIV 
HIV almost certainly arose from a very closely related virus, 
known as SIVcpz (simian immunodeficiency virus), which is 
found in chimpanzees living in parts of Africa7. The virus 
spread from infected chimps to humans when human blood 
came into contact with contaminated chimpanzee blood 
during the hunting of chimpanzees. It is thought that for 
many years, the human form of HIV was limited to a remote 
part of Africa. However, when new transport links opened up 
that part of Africa, the virus spread to other parts of Africa, 
before slowly spreading across the world16. 
TREATING AND LIVING WITH HIV 
Although there is no cure for HIV, treatments are now very 
effective, enabling people with HIV to live long and healthy 
lives. Medication, known as antiretroviral, work by stopping 
the virus replicating in the body, allowing the immune 
system to repair itself and preventing further damage. These 
medicines come in the form of tablets, which need to be 
taken every day19. HIV is able to develop resistance to a 
single HIV drug very easily, but taking a combination of 
different drugs makes this much less likely. Most people with 
HIV take a combination of three antiretroviral and it is vital 
that the medications are taken every day as recommended 
by your doctor. For people living with HIV, taking effective 
antiretroviral therapy (where the HIV virus is "undetectable" 
in blood tests) will significantly reduce the risk of passing on 
HIV to sexual partners. It is rare for a pregnant woman living 
with HIV to transmit it to their babies, provided they receive 
timely and effective antiretroviral therapy and medical care. 
You will also be encouraged to take regular exercise, eat a 
healthy diet, stop smoking and have yearly flu jabs to 
minimize the risk of getting serious illnesses. Without 
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treatment, the immune system will become severely 
damaged and life-threatening illnesses such as cancer and 
severe infections can occur. This is known as late-stage HIV 
infection or AIDS18. 
 PREVENTING HIV 
Anyone who has sex without a condom or shares needles is 
at risk of HIV infection. The best way to prevent HIV is to use 
a condom for sex and to never share needles or other 
injecting equipment (including syringes, spoons and 
swabs).15 Knowing your HIV status and that of your partner 
is also important. For people with HIV, effective 
antiretroviral therapy significantly reduces the risk of 
passing HIV to sexual partners11. 
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